skin-diseases-and-microbiology-2016_scientifictracks

11 / 20

Volume 4, Issue 7(Suppl) J Infect Dis Ther 2016
ISSN: 2332-0877, JIDT an open access journal Skin Diseases & Microbiology 2016
October 03-05, 2016
Page 35
Notes:
conferenceseries.com
Infectious Diseases, Diagnostic Microbiology &
Dermatologists Summit on Skin Infections
October 03-05, 2016 Vancouver, Canada
International Conference on
Phosphorylase kinase inhibition and removal of aggravating factors in the induction of long term remissions in
psoriasis
Phosphorylase kinase (PhK) is a cyclic AMP-dependent dual specificity kinase capable of breaking down glycogen and
phosphorylating both serine/threonine and tyrosine moieties in the activation of the transcription activator, NF-kB, which
in turn is responsible for activating multiple genes responsible for inflammation and cell proliferation. Elevated PhK levels
have been observed to correlate with increased phosphorylation and psoriatic activity, while suppression of PhK activity leads
to resolution of psoriasis. Genes for psoriatic familial susceptibility have been mapped to 17q and psoriasis susceptibility loci
to both 16q and 17q, apparently correlating with genes for the β-subunit of PhK (mapped to 16q) and the regulatory subunit
for cAMP protein kinase (mapped to chromosome 17). These genetic findings provide some credence that defective inhibition
of PhK activity may be responsible for its elevated activity in psoriasis. PhK is released within 5 minutes following injurious
stimuli, including trauma, contact allergens and infections, which serve as aggravating factors in psoriasis. We have developed
a protocol, consisting of inhibition of PhK by its selective inhibitor, curcumin, together with removal of aggravating factors
to achieve not only total clearance of psoriasis, but also to produce long term remissions without the need for maintenance
therapy. In this presentation, we include details of this combination therapy and identification of aggravating factors in our
psoriatic patients.
Biography
Madalene C Y Heng is a Clinical Professor of Medicine, Dermatology at the David Geffen UCLA School of Medicine. From 1979 to 2003, she was a Chief of
Division of Dermatology, UCLA San Fernando Valley Medicine Program. She is currently in private practice in Heng Medical at Camarillo, CA and is a Reviewer for
the Journal of the American Academy of Dermatology, American Journal of Geriatric Medicine, British Journal of Dermatology, Lancet, London, and International
Journal of Angiology. She is the author of more than 140 scientific publications, including 78 published peer-reviewed articles on topics such as phosphorylase
kinase activity and psoriasis, pathophysiology of common skin diseases, and wound healing.
Madalene C Y Heng
David Geffen School of Medicine at UCLA, USA
Madalene C Y Heng, J Infect Dis Ther 2016, 4:7(Suppl)